The Honest Dose #5

I went into this project with a bias I didn't fully recognize until a few weeks in.

When I first started researching peptides, I assumed the space was essentially two things: fitness influencers pushing compounds they'd never actually studied, and broscience communities obsessed with shortcuts to muscle mass. I expected the compounds to mostly be glorified steroids, things that worked in a narrow sense but carried real risks that were being papered over by people whose incentive was selling, not informing. I thought "peptide" was basically a rebranding exercise for the same old supplement-industry playbook.

A month in, that picture looks almost nothing like what I've actually encountered.

The conversations I've had since launching PeptideClear have been genuinely surprising. I've talked to people running Thymosin Alpha-1 protocols because they have chronic viral infections and their doctors had no better options to offer. Someone managing ankylosing spondylitis who found partial relief with a BPC-157 and TB-500 stack after years of inadequate conventional treatment. People using PT-141 after SSRIs killed their libido and their doctors dismissed the problem. Researchers who have devoted entire careers to peptide science not because it pays well but because they believe the therapeutic potential is real and under-explored.

None of that fits the broscience shortcut narrative I came in with. The space is messier, more human, and more interesting than I expected. A lot of the people using compounds with weak evidence aren't reckless, they're people who ran out of good conventional options and made a calculated decision to try something that might help. Whether that's the right call is a separate question. But it's a different story than I thought initially.

I wanted to name that because Issue #5 covers BPC-157, the compound that probably best represents that tension. Weak formal evidence. Overwhelming anecdotal signal. And a research integrity wrinkle that came out of a Reddit thread that I think actually illustrates what PeptideClear is trying to do.

Let's get into it.

BPC-157 stands for Body Protection Compound-157. It's a synthetic pentadecapeptide, a 15-amino acid chain, derived from a protein found in human gastric juice. It was first isolated and studied by Predrag Sikiric and colleagues at the University of Zagreb in Croatia, and essentially all of the foundational research on it has come from that same group.

In the United States it is not FDA approved for any indication. It's sold online as a research chemical, used extensively in the fitness and recovery communities, and discussed in peptide forums with a level of enthusiasm that is almost entirely disconnected from what the formal evidence base actually shows.

That gap, between community signal and clinical evidence, is what makes BPC-157 the most intellectually interesting compound in the catalog.

The proposed mechanisms are numerous. BPC-157 has been studied in animal models for tendon and ligament healing, gut injury repair, nerve regeneration, muscle repair, and reduction of systemic inflammation. It appears to up-regulate growth factor signaling (particularly involving VEGF, which promotes new blood vessel formation), modulate nitric oxide pathways, and interact with both the dopaminergic and serotonergic systems.

The breadth of proposed effects is itself a yellow flag worth noting. Compounds that appear to do everything in preclinical models sometimes do because the models are flawed, or because the effect sizes are exaggerated, or because the research environment isn't generating the kind of negative results that would narrow the picture. The Zagreb group has published hundreds of papers suggesting BPC-157 works across an extraordinary range of conditions. That's either a sign of a genuinely remarkable molecule or a sign of a research program that hasn't been stress-tested by outside groups.

Both things can be partially true.

BPC-157's RQS is currently 20/100 - Insufficient Evidence, updated from 23/100.

Here's what changed, and why I think the change matters.

A few weeks ago I posted about BPC-157 in a peptide research community, a thread asking whether the anecdotal signal around it was worth taking seriously despite the weak formal evidence. The post generated strong engagement, including a comment from a community member who surfaced an Undark investigative piece from February 2026. The piece revealed that Predrag Sikiric, the lead BPC-157 researcher and effectively the entire foundation of the compound's evidence base, holds undisclosed patents through two companies, PharmaCotherapia and Diagen, with direct financial interest in BPC-157's commercial development. Those conflicts were not disclosed in the publications.

This is a meaningful finding. PeptideClear's RQS framework scores Funding Independence out of 10 points precisely because undisclosed commercial conflicts are a documented source of bias in the research literature. Sikiric's original score, acknowledged that the Zagreb group represented a narrow geographic and institutional base, but was not penalized for undisclosed commercial interest because that information wasn't available. With that information now on the record, the score drops to 1/10. Total RQS moves from 23 to 20.

I want to be precise about what that means and what it doesn't.

The RQS is not a measure of whether BPC-157 is safe. It is not a measure of whether it works. It is a measure of the methodological quality and independence of the clinical research supporting the claims made about it. A score of 20/100 means the formal evidence base is weak, narrow, and now known to carry undisclosed conflicts of interest at its foundation. It does not mean the compound doesn't do what thousands of people report it doing. It means we don't have the clinical trial architecture to evaluate that rigorously.

The absence of human RCT data is not proof of inefficacy. It is proof that the question hasn't been answered. Those are different things, and conflating them in either direction, assuming it works because the anecdotes are compelling, or assuming it doesn't work because the trials haven't happened, is the same error in opposite directions.

The thread generated a real conversation about this. What does it mean when anecdotal signal is overwhelming and consistent, but formal evidence is nearly absent?

My position, stated in that thread and worth repeating here: specificity and consistency of anecdotal reports are meaningfully different from raw volume. When the same pattern, accelerated recovery from tendon injuries, reduction in gut inflammation, improved healing timelines, shows up across thousands of independent accounts with similar mechanisms, that's a different kind of signal than "it made me feel good." It doesn't constitute clinical evidence. But it's not noise, either.

The purpose of the RQS isn't to dismiss that signal. It's to be honest that the signal hasn't been validated in the controlled conditions that would let us know how much weight to give it, for which populations, at which doses, with what risk profile. That work hasn't been done.

BPC-157 might be one of the most therapeutically interesting compounds in the catalog. It might also be a case study in how a compelling mechanism and consistent anecdotal signal can survive indefinitely without the clinical trial investment that would actually resolve the question. Both are plausible. The evidence, as it stands, cannot tell us which.

RQS updated: 20/100 - Insufficient Evidence (Funding Independence revised to 1/10 following disclosure of undisclosed commercial conflicts; Sikiric/PharmaCotherapia/Diagen, per Undark February 2026.)

Read the full BPC-157 profile

The claim: Sweating in a sauna flushes toxins from your body. Infrared saunas in particular are marketed as deep-cleaning tools that remove heavy metals, chemicals, and other harmful substances through sweat. The wellness industry has built an entire category around this framing.

The reality: Your liver and kidneys do your detoxing. Sweat is not a meaningful detoxification pathway, and the research doesn't support the claim that saunas meaningfully accelerate toxin removal.

The mechanism doesn't hold up. Detoxification, the actual biological process, is performed by the liver, which converts fat-soluble toxins into water-soluble compounds, and the kidneys, which excrete them through urine. Sweat glands are not equipped to perform this function at scale. Some studies have detected trace amounts of heavy metals like lead, cadmium, and arsenic in sweat, but the quantities are small enough that they make no meaningful difference relative to what the kidneys are already excreting continuously. The liver processes orders of magnitude more than sweat ever could.

The "detox" framing is also semantically slippery in a way worth naming. The word doesn't have a consistent scientific definition when used in wellness contexts. It usually means one of several different things, removing heavy metals, eliminating "environmental chemicals," cleansing the gut, supporting the immune system, and the evidence for each varies independently. Bundling them under one word allows claims to slide between mechanisms without ever being pinned down to a specific, testable prediction.

Here's what sauna use actually has decent evidence for: cardiovascular benefits, particularly in people with existing cardiovascular risk factors, where regular sauna use has been associated with reductions in blood pressure, improved cardiorespiratory fitness when combined with exercise, and reduced all-cause mortality in large Finnish observational studies. Heat shock protein activation. Acute stress reduction. Possible benefit for muscle soreness and recovery. These are real effects with real evidence behind them.

The honest version of the claim: Saunas offer genuine cardiovascular and recovery benefits that are undersold because the "detox" framing is more marketable. The detox claim itself is not supported by the biology or the evidence. Your liver does that job. It's good at it. What saunas actually do well is worth knowing, it's just not what most of the marketing says.

The BPC-157 scoring update is worth explaining in more detail because it illustrates something important about how the RQS is supposed to work, and why it's designed to be a living document rather than a fixed label.

When I originally scored BPC-157, I gave Funding Independence a score of 4/10. The reasoning: the Zagreb group is narrow geographically and institutionally, which limits confidence in the independence of the research, but I had no specific evidence of undisclosed commercial conflicts. The scoring was conservative but not penalizing for something I didn't yet know.

The Undark reporting changed that. Undisclosed conflicts are penalized more heavily in the rubric than disclosed industry funding, because disclosure at least allows readers to calibrate. Hidden conflicts corrupt the evidence record in a way that even industry-funded pre-registered trials do not. Dropping from 4 to 1 reflects that distinction precisely.

This is the kind of update the scoring log was designed to capture. The internal document that accompanies each score is meant to record the reasoning so that when new information surfaces, from investigative journalism, from new publications, from community knowledge, the change can be made and explained, not just silently applied.

If you're ever curious about why a compound scored the way it did, the reasoning is documented at peptideclear.github.io/glossary/scoring-logs/bpc-157.

Retatrutide Phase 3 TRIUMPH-1 results - bariatric surgery-level weight loss from a weekly injection. Eli Lilly released top line data from TRIUMPH-1 in late May. Patients on the highest dose lost an average of 70.3 pounds over 80 weeks, a 28.3% reduction in body weight, and roughly 45% of participants hit the 30% weight loss threshold. A 104-week extension subset with BMI above 35 averaged 85 pounds lost, equal to 30.3% of starting weight. For context, bariatric surgery typically produces 25-35% weight loss. A Phase 3 diabetes trial (TRANSCEND-T2D-1) separately showed up to 2% A1C reduction and nearly 17% weight loss at 40 weeks. Full detailed results will be presented at the American Diabetes Association Scientific Sessions. An FDA submission has not yet been filed, though Lilly has indicated one could come before year-end. PeptideClear covered Retatrutide in Issue #1 when its RQS was 59/100 with Phase II data only, Phase III pending. That score is being updated.

Seven more Phase 3 TRIUMPH readouts expected from Lilly in 2026. Beyond TRIUMPH-1 and TRANSCEND-T2D-1, Lilly's Retatrutide Phase 3 program includes trials in patients with cardiovascular disease, obstructive sleep apnea, knee osteoarthritis, and metabolic liver disease. TRIUMPH-4, the osteoarthritis trial, has already reported, patients lost an average of 71 pounds alongside a 75.8% reduction in WOMAC knee pain scores. The program has enrolled over 5,800 participants across trials. If even half the remaining readouts are positive, retatrutide will arrive at the FDA with one of the most comprehensive obesity trial programs ever assembled.

A compound that deserves more mainstream attention than it gets, partly because it gets lumped in with the growth hormone gray market when it doesn't belong there.

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically the first 29 amino acids of the naturally occurring peptide. It works by stimulating the pituitary gland to produce and release more of your own growth hormone, rather than introducing exogenous HGH directly. That distinction matters both mechanically and regulatorily.

Sermorelin was previously FDA approved under the brand name Geref for treatment of growth hormone deficiency in children. The manufacturer discontinued it commercially in 2008, not because of safety issues, but because recombinant HGH became the preferred clinical standard. It remains available through compounding pharmacies with a valid prescription, and it sees off-label use in adults for body composition, sleep quality, and anti-aging applications.

The evidence base is moderate. Multiple human RCTs have demonstrated GH stimulation and some body composition effects. The growth hormone-stimulating effect is well-replicated across independent groups. Where the evidence gets thinner is in the body composition and anti-aging claims for healthy adults, the trials there are smaller, less consistently positive, and often conducted in patients with specific deficiency rather than healthy middle-aged adults seeking optimization.

RQS: 64/100 - Moderate Evidence

It's one of the more accessible entry points in the growth hormone category for people interested in the evidence-based side of GH optimization, prescription-accessible, previously FDA-approved, mechanistically distinct from direct HGH supplementation, and with a cleaner regulatory history than most compounds in this part of the catalog.

Read the full Sermorelin profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.